Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK based Vernalis has completed dosing of the first patient in a placebo controlled Phase I trial evaluating V81444 in patients with Parkinson's disease (PD).
Subscribe to our email newsletter
The trial, which will be conducted in healthy male volunteers, is a combined single and multiple ascending dose safety, tolerability and pharmacokinetic trial.
The company expects to evaluate around 32 subjects for a period of 14 days at four different dose levels.
Vernalis CEO Ian Garland said V81444’s progression into Phase I is an important milestone for Vernalis as they continue to study this potentially high value development programme.
"The A2A target has already been validated in other Parkinson’s disease programmes and this Phase I study is the first step in establishing the safety and pharmacokinetic profile of our A2A programme," Garland said.